LIQUIDIA CORP
LQDANASDAQTrading Snapshot
- Day Range
- $67.97 – $69.74
- 52-Week Range
- $21.15 – $93.61
- Volume
- $2.80B
- Avg Volume
- $2.52B
- Shares Outstanding
- 88.9M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $158M
- Last Q Revenue
- $172M
- P/E Ratio
- 47.6
- P/S Ratio
- 14.6x
- EPS (TTM)
- $1.39
- Dividend Yield
- —
- Dilution (1yr)
- +18.1%
Why Investors Own LQDA
- ✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LIQUIDIA CORP
LQDA
StockOtter · stockotter.spaceAbout LIQUIDIA CORP
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Is It Too Late to Buy Liquidia Corp (LQDA) After 7.7% Rally? GF Value Says Undervalued
On September 28, 2026, Liquidia Corp (LQDA) shares rose by 7.7%, reaching a current price of $73.67. This impressive move comes within a 52-week range of $21.35
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.
California State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDA
California State Teachers Retirement System raised its holdings in shares of Liquidia Corporation (NASDAQ: LQDA) by 8,055.4% in the undefined quarter, according to the company in its most recent disclosure with the Secur
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients No therapy is